From: Methylated DNA/RNA in Body Fluids as Biomarkers for Lung Cancer
DNA methylation | Body fluid | Method | Number of cases | Number of controls | Sensitivity (%)/specificity (%) or main findings | References |
---|---|---|---|---|---|---|
SHOX2 | plasma | qMSP | 222 | 189 | 60/90 | [76] |
plasma | qMSP | 38 | 31 | 80.65/78.57 | [46] | |
DCLK1 | plasma | qMSP | 65 | 95 | 49.2/91.6 | [17] |
SEPT9 | plasma | qMSP | 75 | 100 | 44.3/92.3 | [106] |
IEAA | blood | HM450K | 43 | 1986 | one unit increase in IEAA was associated with 50% higher risk for LC | [107] |
RARβ2 | plasma | MSP | 52 | 26 | 63/51 | [50] |
csbDNA | MSP | 52 | 26 | 70/63 | [50] | |
DLEC1 | plasma | MSP | 78 | 50 | 36/98 | [85] |
CDH1 | serum | qMSP | 76 | 30 | 62/70 | [79] |
DCC | serum | qMSP | 76 | 30 | 35.5/100 | [79] |
CDH13 | plasma | MSP | 63 | 36 | 33/83 | [108] |
P16 | serum | MSP | 22 | 0 | 14% | [81] |
plasma | F-MSP | 35 | 15 | 40/100 | [82] | |
plasma | modified semi-nested MSP | 105 | 0 | 73% | [83] | |
Plasma | F-MSP | 30 | 30 | 50% | [57] | |
EBC | F-MSP | 30 | 30 | 40% | [57] | |
DAPK | serum | MSP | 22 | 0 | 18% | [81] |
serum | NA | 50 | 0 | 40% | [80] | |
GSTP1 | serum | MSP | 22 | 0 | 5% | [81] |
MGMT | serum | MSP | 22 | 0 | 18% | [81] |
TMS1 | serum | NA | 50 | 0 | 34% | [80] |
RASSFS1A | serum | NA | 50 | 0 | 34% | [80] |
blood cell | NA | NA | NA | positive with LC diagnosis. | [75] | |
APC | Serum/plasma | MSP | 89 | 50 | 47% | [84] |
LINE-1 | csbDNA | MIRA | 56 | 44 | AUC0.69 | [49] |
Buffy coat DNA | PCR pyrosequencing | 34 | 360 | Hypomethylation is associated with 3.2-fold higher risk for LC | [51] | |
p53 | peripheral lymphocyte DNA | HpaII quantitative PCR | 100 | - | Hypomethylation was associated with a 2-fold increased risk for LC | [52] |